SLC13A3 and neoplasm: Tumor cells take up itaconic acid from tumor-associated macrophages (TAMs) via SLC13A3, activating the NRF2-SLC7A11 pathway to evade ferroptosis mediated by the immune system and develop resistance to immune checkpoint blockade therapy.